Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 1/2013

01.01.2013 | Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

The Prognostic Value of Late Gadolinium Enhancement CMR in Nonischemic Cardiomyopathies

verfasst von: Theodoros D. Karamitsos, Stefan Neubauer

Erschienen in: Current Cardiology Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular magnetic resonance (CMR) is a valuable clinical tool in everyday practice providing additional information to echocardiography. The late gadolinium enhancement (LGE) technique is now part of nearly every CMR protocol and enables in-vivo tissue characterization in ischemic (identification of scaring due to infarction) and many nonischemic cardiomyopathies (identification of regional or patchy fibrosis or infiltration). This review presents the evolving prognostic evidence base of LGE-CMR with a particular focus on nonischemic cardiomyopathies. Novel methods to assess diffuse myocardial fibrosis such as pre- and post-contrast T1-mapping are also discussed.
Literatur
1.
Pohost GM. The history of cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2008;1:672–8.PubMedCrossRef
2.
Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–24.PubMedCrossRef
3.
Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial gd-dtpa kinetics determine mri contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.PubMedCrossRef
4.
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of mri delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002.PubMedCrossRef
5.
Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced mri and routine single photon emission computed tomography (spect) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374–9.PubMedCrossRef
6.
•• Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53. Landmark study which established the use of late gadolinium enhancement to predict regional function post revascularization.
7.
Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535–41.PubMedCrossRef
8.
• Pegg TJ, Selvanayagam JB, Jennifer J, Francis JM, Karamitsos TD, Dall'Armellina E, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:56. An important paper which describes the ability of late gadolinium enhancement to predict not only regional but also global recovery of function post revascularization.
9.
Cheong BY, Muthupillai R, Wilson JM, Sung A, Huber S, Amin S, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120:2069–76.PubMedCrossRef
10.
Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2:34–44.PubMedCrossRef
11.
Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733–43.PubMedCrossRef
12.
Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011–20.PubMedCrossRef
13.
Rahimi K, Banning AP, Cheng AS, Pegg TJ, Karamitsos TD, Channon KM, et al. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart. 2009;95:1937–43.PubMedCrossRef
14.
Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115:2006–14.PubMedCrossRef
15.
Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–9.PubMedCrossRef
16.
Karamitsos TD, Francis JM, Neubauer S. The current and emerging role of cardiovascular magnetic resonance in the diagnosis of nonischemic cardiomyopathies. Prog Cardiovasc Dis. 2011;54:253–65.PubMedCrossRef
17.
Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727–32.PubMedCrossRef
18.
McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.PubMedCrossRef
19.
•• Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85. An important paper which describes the prognostic value of midwall fibrosis in patients with dilated cardiomyopathy.
20.
Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821–5.PubMedCrossRef
21.
Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.PubMedCrossRef
22.
Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821–8.PubMedCrossRef
23.
Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J. 2012;33:640–8.PubMedCrossRef
24.
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.PubMedCrossRef
25.
Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53:284–91.PubMedCrossRef
26.
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184–91.PubMedCrossRef
27.
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.PubMedCrossRef
28.
Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced mri study. Int J Cardiovasc Imaging. 2008;24:617–25.PubMedCrossRef
29.
• O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
30.
• Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
31.
Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
32.
Appelbaum E, Maron BJ, Adabag S, Hauser TH, Lesser JR, Haas TS, et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:78–85.PubMedCrossRef
33.
Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–41.PubMedCrossRef
34.
Hunold P, Wieneke H, Bruder O, Krueger U, Schlosser T, Erbel R, et al. Late enhancement: a new feature in mri of arrhythmogenic right ventricular cardiomyopathy? J Cardiovasc Magn Reson. 2005;7:649–55.PubMed
35.
Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98–103.PubMedCrossRef
36.
Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance in heart failure. Curr Cardiol Rep. 2011;13:210–9.PubMedCrossRef
37.
Childs H, Friedrich MG. Cardiovascular magnetic resonance imaging in myocarditis. Prog Cardiovasc Dis. 2011;54:266–75.PubMedCrossRef
38.
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a jacc white paper. J Am Coll Cardiol. 2009;53:1475–87.PubMedCrossRef
39.
•• Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604–15. This study assessed the prognostic value of late gadolinium enhancement in patients with myocarditis.
40.
• Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2:1369–77. This study assessed the prognostic value of late gadolinium enhancement in patients with amyloidosis.
41.
Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–93.PubMedCrossRef
42.
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3:155–64.PubMedCrossRef
43.
Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022–30.PubMedCrossRef
44.
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54.PubMedCrossRef
45.
Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011;13(11):1231–7. doi:10.​1093/​eurjhf/​hfr099.
46.
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77.PubMedCrossRef
47.
Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–90.PubMedCrossRef
48.
Karamitsos TD, Myerson SG. The role of cardiovascular magnetic resonance in the evaluation of valve disease. Prog Cardiovasc Dis. 2011;54:276–86.PubMedCrossRef
49.
• Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–9. This study assessed the prognostic value of late gadolinium enhancement in patients with aortic stenosis.
50.
Blyth KG, Groenning BA, Martin TN, Foster JE, Mark PB, Dargie HJ, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26:1993–9.PubMedCrossRef
51.
Shehata ML, Lossnitzer D, Skrok J, Boyce D, Lechtzin N, Mathai SC, et al. Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am J Roentgenol. 2011;196:87–94.PubMedCrossRef
52.
Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14:11.PubMedCrossRef
53.
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the uk and relation to t2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.PubMedCrossRef
54.
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac t2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961–8.PubMedCrossRef
55.
Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:8.PubMedCrossRef
56.
• White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart. 2012;98:773–9. Interesting review article which summarizes the role of CMR and other imaging modalities in the characterisation of myocardial interstitial space.
57.
Piechnik SK, Ferreira VM, Dall'armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened modified look-locker inversion recovery (shmolli) for clinical myocardial t1-mapping at 1.5 and 3 t within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.PubMedCrossRef
58.
Dall'Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, et al. Cardiovascular magnetic resonance by non contrast t1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson. 2012;14:15.PubMedCrossRef
59.
Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, et al. Myocardial t1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007;58:34–40.PubMedCrossRef
60.
Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Choudhury RP, et al. Non-contrast t1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to t2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.PubMedCrossRef
61.
•• Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44. One of the first studies showing the ability of CMR to assess diffuse fibrosis in hypertrophic cardiomyopathy and aortic stenosis.
62.
Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ-Cardiovasc Imaging. 2010;3:727–34.PubMedCrossRef
63.
• Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234–42. One of the first studies showing the ability of CMR to assess diffuse fibrosis in patients with dilated cardiomyopathy.
64.
Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced t1 mapping. J Am Coll Cardiol. 2008;52:1574–80.PubMedCrossRef
Metadaten
Titel
The Prognostic Value of Late Gadolinium Enhancement CMR in Nonischemic Cardiomyopathies
verfasst von
Theodoros D. Karamitsos
Stefan Neubauer
Publikationsdatum
01.01.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 1/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0326-2

Weitere Artikel der Ausgabe 1/2013

Current Cardiology Reports 1/2013 Zur Ausgabe

New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

Platelet Function Monitoring and Clopidogrel

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Modeling of Fractional Flow Reserve Based on Coronary CT Angiography

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Coronary Calcium: New Insights, Recent Data, and Clinical Role

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Transcatheter Aortic Valve Repair, Imaging, and Electronic Imaging Health Record

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Percutaneous Versus Surgical Interventions for Coronary Artery Disease in Those with Diabetes Mellitus

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Imaging of Inflammation and Calcification in Aortic Stenosis

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen